Merck & Co.: A Pharma Titan At A Discount

Merck & Co. (MRK) shares are down approximately 18% year-to-date, attributed to the impending 2028 patent cliff, subdued Gardasil demand in China, and IRA price controls. Despite these headwinds, an analyst's discounted cash flow model indicates MRK is up to 23% undervalued, citing robust underlying fundamentals, substantial R&D investment, and a planned $20 billion capital expenditure expansion from 2024 to 2028. This analysis leads to a short-term bullish outlook and a buy recommendation for the stock.

Analysis

Merck & Co. (MRK) has experienced significant stock price underperformance, declining approximately 18% year-to-date due to a confluence of market headwinds. Key investor concerns include the approaching 2028 patent cliff, weakened demand for its Gardasil vaccine in China, and potential margin pressure from U.S. IRA price controls. Despite these challenges, an analyst's discounted cash flow (DCF) model presents a contrarian view, suggesting the stock is undervalued by as much as 23% at its current trading levels. This bullish thesis is underpinned by the company's strong underlying fundamentals, including robust margins and a commitment to heavy R&D investment. Furthermore, Merck has outlined a clear strategic growth initiative, with a planned capital expenditure of $20 billion between 2024 and 2028 aimed at aggressive expansion, signaling a proactive approach to offsetting the identified risks.

Key Decisions for Investors

• Given the disconnect between the 18% YTD stock decline and the analyst's valuation model indicating a 23% upside, investors may consider the current price a potential entry point for a long position.
• Investors should closely monitor key risk factors, namely any new developments regarding the 2028 patent cliff, sales figures for Gardasil in China, and the realized impact of IRA price negotiations.
• The execution and return on the planned $20 billion capital expenditure program should be tracked as a primary catalyst for future growth and a key indicator of the company's ability to navigate its current headwinds.